Uveitis: Protecting Your Vision From Eye Inflammation
Understanding Uveitis
Uveitis refers to inflammation of the uvea, the middle layer of the eye. The uvea contains many blood vessels that deliver oxygen and nutrients to eye tissue. When these tissues become inflamed, the swelling and damage can interfere with vision. Uveitis is not a single disease. It represents a collection of over 30 different inflammatory conditions affecting the eye.
The uvea has three main structures. The iris is the colored part of the eye that controls how much light enters. The ciliary body sits behind the iris and produces the fluid inside the eye. The choroid is a layer of blood vessels that lines the back of the eye beneath the retina. Inflammation can affect one or more of these structures.
Uveitis is classified by which part of the eye is inflamed. The four types are:
- Anterior uveitis: the most common form, affecting the iris and ciliary body at the front of the eye
- Intermediate uveitis: affects the vitreous gel and the area just behind the ciliary body
- Posterior uveitis: involves the choroid and retina at the back of the eye
- Panuveitis: inflammation that extends through all layers of the uvea
When the immune system triggers inflammation inside the eye, white blood cells and proteins flood into eye tissue. In anterior uveitis, these inflammatory cells spill into the chamber behind the cornea. In posterior uveitis, inflammation targets the choroid or retina directly. This process can damage delicate tissues and cause swelling in the macula. The macula is the central part of the retina responsible for sharp vision. Uncontrolled inflammation can lead to severe and lasting vision loss.
Uveitis can follow different patterns over time. Acute uveitis develops suddenly and may resolve within weeks with treatment. Recurrent uveitis involves repeated episodes separated by inactive periods. Chronic uveitis persists for months or years and requires ongoing therapy to keep inflammation under control.
Who Is Affected and Risk Factors
Noninfectious uveitis affects approximately 121 per hundreds of thousands adults in the United States. In children, the prevalence is about 29 per hundreds of thousands (Thorne et al., JAMA Ophthalmology, 2016). While uveitis can occur at any age, it most often affects young adults between the ages of 20 and 60.
An estimated 80% to 90% of uveitis cases in developed countries are noninfectious (AAO, 2023). This means they are not caused by a germ. Many of these cases are linked to autoimmune or inflammatory conditions. In these conditions, the body's immune system mistakenly attacks its own tissues. Conditions commonly associated with uveitis include sarcoidosis, Behcet disease, and Vogt-Koyanagi-Harada syndrome. In children, juvenile idiopathic arthritis is a major risk factor.
A genetic marker called HLA-B27 plays a significant role in uveitis risk. HLA-B27 associated uveitis is the most common known cause of noninfectious uveitis in the developed world (Frontiers in Medicine, 2021). HLA-B27 is present in about 6.1% of the overall US population and 7.5% of non-Hispanic white individuals (Frontiers in Medicine, 2021). People who carry this marker and also have conditions such as ankylosing spondylitis or psoriatic arthritis face an elevated risk.
Some uveitis cases are caused by infections, including syphilis, tuberculosis, and herpes viruses. These infectious forms require specific antimicrobial treatment in addition to anti-inflammatory therapy. Smoking has been associated with increased risk in some studies. A thorough evaluation by a retina specialist or uveitis specialist can help determine the underlying cause. Identifying whether the cause is infectious or noninfectious directly affects the treatment plan.
Signs and Symptoms
The symptoms of uveitis depend on the type and location of inflammation. General symptoms that may occur include:
- Eye pain, often described as a deep ache
- Redness of the eye
- Photophobia (sensitivity to light)
- Blurred or decreased vision
- Floaters (dark spots or strings drifting across your field of vision)
Anterior uveitis, the most common form, tends to develop rapidly over a few days. It typically causes noticeable pain, redness, and light sensitivity. Patients may also notice a smaller pupil in the affected eye or tearing. These symptoms often prompt people to seek care quickly.
Posterior uveitis can be more difficult to detect early. It may develop gradually with no pain or redness. The first noticeable symptom is often blurred vision or floaters. Because it affects the retina and choroid at the back of the eye, significant damage can occur before a person realizes something is wrong. This is one reason why routine dilated eye exams are important for people with known risk factors.
Certain symptoms require immediate attention. See a retina specialist or go to the emergency room right away if you experience sudden eye pain, a rapid increase in floaters, flashes of light, or sudden vision loss. Delayed treatment of uveitis can result in severe and lasting vision damage.
Diagnosis and Testing
A retina specialist or uveitis specialist will begin with a detailed eye examination. This includes a slit-lamp exam. The slit lamp is a special microscope that uses a narrow beam of light to view the structures inside the eye. The specialist looks for inflammatory cells in the fluid chambers, protein deposits on the inner cornea, and signs of retinal swelling or damage.
Several imaging tools help evaluate the extent of inflammation. Optical coherence tomography (OCT) creates detailed cross-sectional images of the retina. OCT can detect macular edema (swelling of the central retina). Fluorescein angiography uses a special dye injected into a vein to reveal leaking blood vessels. These tests help guide treatment decisions and track response over time.
Because uveitis is often connected to a systemic condition, blood tests and other laboratory work may be ordered. Common tests check for HLA-B27, markers of sarcoidosis, syphilis, tuberculosis, and other autoimmune markers. In some cases, imaging of the chest or other body areas may be needed. The goal is to identify any underlying cause so that both the eye inflammation and the root condition can be treated together.
Treatment Options
For anterior uveitis, corticosteroid eye drops are usually the first line of treatment. These drops reduce inflammation inside the eye. The specialist may also prescribe dilating drops to relieve pain and prevent the iris from sticking to the lens. Treatment is typically tapered slowly rather than stopped abruptly.
When inflammation affects the back of the eye or does not respond well to drops, a retina specialist may recommend steroid injections or implants. Ozurdex (dexamethasone implant) is approved for noninfectious posterior uveitis and releases medication over three to four months. YUTIQ (fluocinolone acetonide 0.18 mg) is a tiny implant approved for chronic noninfectious posterior uveitis. It provides sustained drug release for up to 36 months. Retisert (fluocinolone acetonide 0.59 mg) is a surgically implanted device that delivers medication for 30 to 36 months. These options reduce the need for frequent eye drops or systemic medications in some patients.
For patients with noninfectious intermediate, posterior, or panuveitis who need stronger systemic treatment, Humira (adalimumab) is an FDA-approved biologic therapy. It works by blocking tumor necrosis factor-alpha, a protein that drives inflammation. Humira is given as a self-administered injection under the skin, typically every two weeks. Long-term data from the VISUAL III extension study show sustained disease control in 60% to 90% of patients at 78 weeks (JAMA Ophthalmology, 2019). Since 2023, multiple adalimumab biosimilars have become available, expanding access to this treatment.
When corticosteroids alone are not enough, a retina specialist may recommend immunosuppressive medications. Long-term steroid use can create concerning side effects, making these alternatives important. These drugs are often used off-label for uveitis. They include methotrexate, mycophenolate, azathioprine, and cyclosporine. Infliximab, another biologic agent, is also used off-label. These drugs work by calming the overactive immune response that drives chronic uveitis. Regular blood work is needed to monitor for side effects.
When uveitis causes macular edema, additional targeted treatment may be necessary. Avastin (bevacizumab), which is FDA-approved for cancer but used off-label for eye conditions, may be injected into the eye to reduce swelling. Clinical trials are also investigating newer treatments. These include vamikibart, an anti-IL-6 agent being studied in the MEERKAT and SANDCAT clinical trials for uveitic macular edema.
What to Expect
Treatment for uveitis often involves frequent office visits, especially at the start. A retina specialist will monitor inflammation levels closely and adjust medication as needed. Steroid eye drops may need to be used several times per day initially and then slowly reduced. Patients receiving injections or implants will have the procedure performed in the office or an outpatient surgical setting. The specialist will check for side effects such as increased eye pressure or cataract formation.
The course of uveitis varies widely depending on the type, cause, and severity. Some patients experience a single episode of anterior uveitis that resolves completely with treatment. Others face recurrent flare-ups or chronic inflammation requiring years of therapy. Early detection and consistent treatment offer the best chance of preserving vision. However, some patients may develop complications such as glaucoma, cataracts, or retinal scarring even with appropriate care.
Long-term monitoring is a key part of uveitis management. Chronic inflammation or prolonged steroid use can lead to elevated eye pressure, cataracts, or macular edema. Retinal damage and band keratopathy (calcium deposits on the cornea) are also possible. Regular dilated eye exams and imaging tests help catch these problems early. This allows them to be managed before significant vision loss occurs.
Living With Uveitis
Uveitis often requires a team approach. A retina specialist or uveitis specialist manages the eye inflammation. A rheumatologist or other physician may manage the underlying systemic condition. Keeping all of your doctors informed about your treatment plan and any changes in symptoms helps ensure coordinated care. Do not stop medications without consulting your specialist, as abruptly discontinuing treatment can trigger a flare.
Wearing sunglasses can help manage light sensitivity during active flares. If you smoke, quitting may reduce your risk of worsening inflammation. Maintaining a healthy lifestyle with a balanced diet and regular exercise supports overall immune health. Keep a record of your symptoms, including when flares occur and what may have triggered them. Share this record with your specialist at each visit.
Living with a chronic eye condition can be stressful, especially when vision is affected. It is normal to feel anxious about flare-ups or long-term vision outcomes. Connecting with patient support organizations focused on uveitis or autoimmune conditions can provide valuable information and emotional support. Ask your retina specialist about resources that may be available to you.
When to See a Retina Specialist
Contact a retina specialist or go to the emergency room immediately if you experience sudden eye pain, a rapid increase in floaters, flashes of light, or sudden blurred vision. A shadow or curtain across part of your vision also requires emergency evaluation. These symptoms may indicate a serious flare or a complication that needs prompt treatment to protect your remaining vision.
If you have been diagnosed with an autoimmune or inflammatory condition associated with uveitis, ask your doctor about a referral to a retina specialist. A baseline eye examination is important even without symptoms. Regular screening can detect early signs of inflammation. If you have had uveitis in the past, continue with scheduled follow-up visits. Recurrence is common, and catching it early improves outcomes.
Questions and Answers
Stress alone is not a direct cause of uveitis. However, stress can affect the immune system in ways that may trigger flares in people with an underlying autoimmune condition. Managing stress through healthy habits may help reduce flare frequency, but it is not a substitute for medical treatment.
Not all patients with uveitis need injections. Many cases of anterior uveitis are managed with eye drops alone. However, intermediate, posterior, or panuveitis may require steroid injections, intravitreal implants, or biologic injections such as Humira (adalimumab). Your retina specialist will recommend the least invasive effective treatment based on the type and severity of your condition.
No. Pink eye, or conjunctivitis, is inflammation of the outer membrane covering the white of the eye. Uveitis is inflammation inside the eye, affecting deeper structures such as the iris, ciliary body, choroid, and retina. Uveitis is more serious and carries a greater risk of vision loss. While both can cause redness, uveitis also causes pain, light sensitivity, and vision changes that pink eye typically does not.
Yes. Uveitis occurs in children, with a prevalence of about 29 per 100,000 (Thorne et al., JAMA Ophthalmology, 2016). Children with juvenile idiopathic arthritis are at particular risk. In children, uveitis may cause few or no symptoms at first. This makes regular screening eye exams essential for early detection. A pediatric retina specialist or uveitis specialist can provide appropriate evaluation and treatment.
Treatment duration depends on the type of uveitis. A single episode of acute anterior uveitis may resolve with a few weeks of eye drops. Chronic or recurrent forms may require months or years of treatment. This can include immunosuppressive medications or long-acting implants. Your retina specialist will adjust the treatment plan over time based on how well inflammation is controlled.